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ABSTRACT: On the basis of the long-known prototypic
pharmacophore 3-(1H-imidazol-4-yl)propylguanidine (SK&F
91486, 2), monomeric, homodimeric, and heterodimeric
bisalkylguanidine-type histamine H2 receptor (H2R) agonists
with various alkyl spacers were synthesized. Aiming at
increased H2R selectivity of the ligands, the imidazol-4-yl
moiety was replaced by imidazol-1-yl, 2-aminothiazol-5-yl or 2-
amino-4-methylthiazol-5-yl according to a bioisosteric ap-
proach. All compounds turned out to be partial or full agonists
at the h/gp/rH2R. The most potent analogue, the thiazole-type
heterodimeric ligand 63 (UR-Po461), was a partial agonist
(Emax = 88%) and 250 times more potent than histamine (pEC50: 8.56 vs 6.16, gpH2R, atrium). The homodimeric structures 56
(UR-Po395) and 58 (UR-Po448) exhibited the highest hH2R aﬃnities (pKi: 7.47, 7.33) in binding studies. Dimeric
amino(methyl)thiazole derivatives, such as 58, generated an increased hH2R selectivity compared to the monomeric analogues,
e.g., 139 (UR-Po444). Although monomeric ligands showed up lower aﬃnities and potencies at the H2R, compounds with a
short alkylic side chain like 129 (UR-Po194) proved to be highly aﬃne hH4R ligands.
1. INTRODUCTION
In humans, the histamine receptor family comprises four
subtypes, namely, H1, H2, H3, and H4 receptors.
1−4 They are
activated by the biogenic amine histamine (1, Figure 1)5 and
belong to the superfamily of G-protein-coupled receptors
(GPCRs).6 For more than three decades, 3-(1H-imidazol-4-
yl)propylguanidine (SK&F 91486, 2, Figure 1)7 has been used
as prototypic pharmacophore for the synthesis of highly potent
histamine H2-receptor (H2R) agonists of the guanidine class,
e.g., compounds such as arpromidine (3, Figure 1).8 The
application of the bivalent ligand approach to acylguanidine-
type H2R agonists by Birnkammer et al. led to highly potent
and selective H2R agonists, e.g., UR-AK 381 (4, Figure 1),
raising questions about the binding mode and usability of such
dimeric ligands as pharmacological tools.9 Insuﬃcient chemical
stability of these acylguanidines, due to hydrolytic cleavage, led
to carbamoylguanidine-type H2R agonists, which proved to be
stable.10 As many class A GPCRs were reported to form homo-
and heterodimers, bivalent ligands can potentially be used as
pharmacological tools to investigate the binding mode.11,12
Using diﬀerent spacer lengths, Birnkammer et al. showed that
an interaction of the second pharmacophore with an allosteric
binding site at the same receptor protomer is more likely than
binding to the second orthosteric binding site of an H2R
homodimer.9
For a better understanding of the structure−activity
relationship of bisalkylguanidine-type dimeric H2R ligands, we
prepared and pharmacologically characterized several mono-
meric and dimeric compounds derived from the recently
reported homodimeric H2R agonist SK&F 93082 (5, Figure
1).13 In particular, the inﬂuence of diﬀerent heteroaromatic ring
systems and diﬀerent spacer lengths on histamine receptor
subtype selectivity was studied, using radioligand binding assays
to investigate the aﬃnities to the respective receptors.
Investigations on H2R species selectivity were performed
involving recombinant human, guinea pig, and rat H2Rs
([35S]GTPγS binding assay),14 which gave information about
the type, aﬃnity/potency, and eﬃcacy of the receptor ligand.
Organ pharmacological studies (gpH1R (ileum), gpH2R (right
atrium))15,16 aﬀorded agonistic (H2R) and antagonistic (H1R)
activities under more physiological conditions. Functional
activities on the guinea pig ileum and right atrium were
measured via the contractility of the tissue and the increase of
the heart frequency, respectively. The main focus of this project
was the development of H2R agonists. This also includes the
characterization of numerous compounds at the other
histamine receptors (H1,3,4R), which led to the identiﬁcation
of selective H4R ligands.
2. RESULTS AND DISCUSSION
2.1. Chemistry. The structures of amines 6−9, which were
used for the synthesis of compounds 5, 53−63, 127−141, and
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145, are depicted in Figure 2. For the preparation of the
dimeric ligands, the diamines 11−16 were treated with benzoyl
isothiocyanate (10) to give the corresponding dibenzoylthiour-
eas 17−22 (Scheme 1) via nucleophilic addition, followed by
alkaline hydrolysis yielding the bisthioureas 23−28 as
described.17,8 After S-methylation using methyl iodide, the
bis(S-methylisothioureas) 29−34 were Boc-protected to give
the guanidinylation reagents 35−40 (Scheme 1) following
reported procedures.8,18 The homodimeric ligands 5, 53−60
were obtained by treating amines 6, 7, 8, or 9 (each 2 equiv)
with some of the guanidinylation reagents 35−40 in the
presence of HgCl2 (2 equiv) and triethylamine (NEt3),
19
followed by Boc deprotection of the intermediates 41−49. The
heterodimeric ligands 61−63 were synthesized by treatment of
the guanidinylating reagent 38 with an equimolar mixture of
two diﬀerent amines (6 and 7, 6 and 8, or 7 and 8), followed by
deprotection of the intermediates 50−52 using triﬂuoroacetic
acid (TFA, Scheme 1). It should be mentioned that the use of
more than 2 equiv of HgCl2 led to a decrease in yield,
presumably due to conversion of one S-methylisothiourea
moiety to the respective carbodiimide as described in the
literature.18,19
The synthetic strategy for the dimeric compounds was also
used for the synthesis of the monomeric compounds 127−141
(Scheme 2). Although the alkylated thioureas 82−87 were
commercially available, 76−81 had to be synthesized by
nucleophilic addition of the corresponding amine (64−69)
with 10 to give 70−75, followed by alkaline hydrolysis yielding
the desired compounds (cf. Scheme 2). S-methylation (88−
99), Boc-protection (100−111), and guanidinylation (112−
126) were accomplished as described for the dimeric ligands
with adapted amount of substance (Scheme 2). Finally, the
precursors 112−126 were deprotected using TFA to give 127−
141 (Scheme 2).
The cyclic guanidine derivative N-[3-(1H-imidazol-4-yl)-
propyl]-1,4,5,6-tetrahydropyrimidin-2-amine (145) was pre-
pared in a three-step synthesis starting from tetrahydropyr-
imidine-2(1H)-thione (142) (Scheme 3). Di-Boc-protection of
142 in the presence of sodium hydride resulted in 143 (Scheme
3), as described.20 After guanidinylation with 6, intermediate
144 was treated with TFA to receive 145 (Scheme 3).
2.2. Stability of Dimeric Alkylguanidines. The chemical
stability of the bisalkylguanidine-type dimeric HR ligands was
exemplarily investigated for compounds 57 and 58, which were
incubated in a binding buﬀer (BB, pH 7.4) at a concentration of
100 μM at room temperature for 12 months. Reversed-phase
high-performance liquid chromatography (RP-HPLC) analysis
revealed that 57 and 58 exhibited, in contrast to the previously
reported acylguanidine-type HR ligands,10 excellent chemical
stabilities (Figure 3).
2.3. Pharmacology. The synthesized dimeric (5, 53−63)
and monomeric (127−141 and 145) ligands were investigated
in radioligand competition binding assays (hH1,2,3,4R), in the
[35S]GTPγS binding assay (hH2,3,4R, gp/rH2R), in the guinea
pig ileum assay (gpH1R), and in the guinea pig right atrium
assay (gpH2R). For the radioligand and the GTPγS binding
assay, membranes of Sf9 cells, expressing hH1R + RGS4, h/gp/
rH2R + Gsαs, hH3R + Giα2 + Gβ1γ2, or hH4R Giα2 + Gβ1γ2,
were used.
2.3.1. Receptor Subtype Selectivity. To investigate the
aﬃnities of 5, 53−63, 127−141, and 145 at the four hHR
subtypes, competition binding studies were performed using
the radioligands [3H]mepyramine (hH1R), [
3H]tiotidine or
[3H]UR-DE25721 (hH2R), [
3H]Nα-methylhistamine (hH3R),
and [3H]histamine (hH4R). The imidazol-4-yl-type homodi-
meric ligands 56 and 57, containing a decamethylene and a
dodecamethylene spacer, respectively, exhibited the highest
aﬃnities at every HR subtype with the following selectivity
proﬁle: pKi H1R < H2R ≈ H3R ≈ H4R (Table 1). The same
selectivity proﬁle was evident for the homodimeric compounds
5 and 53−55. The 2-amino-4-methylthiazol-5-yl- and 2-
aminothiazol-5-yl-type homodimeric ligands 58 and 59,
respectively, as well as the 2-amino-4-methylthiazol-5-yl/2-
aminothiazol-5-yl-type heterodimeric compound 63 proved to
be selective H2R ligands with at least 1.5 log units diﬀerence in
pKi (H2R) over pKi (H1,3,4R) (Table 1). This demonstrated
that replacement of the imidazol-4-yl by an 2-aminothiazol-5-yl
moiety is bioisosteric with respect to H2R binding, but not in
Figure 1. Structures of histamine and selected H2R agonists (2−5).
Figure 2. Structures of the building blocks 6−9, which were used for the preparation of the dimeric and monomeric compounds 5, 53−63, 127−
141, and 145 (cf. scheme 1−3).
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case of H3 and H4 receptor binding, and was in accordance with
previous reports on 2-aminothiazol-5-yl-type H2R selective
ligands.22 The binding data at the hH1R showed values, which
were dependent from the spacer length, respectively the
lipophilicity. The replacement of imidazol-4-yl by a imidazol-1-
yl ring (60) leads to a collapse of the aﬃnities at all histamine
receptor subtypes. The monomeric reference substances 127−
141 and 145 displayed increasing aﬃnities at the hH2R with
respect to their chain length, but lower aﬃnities compared to
the respective dimeric compounds. Overall, the aﬃnities at the
hH3,4Rs were higher, except of the aminothiazole-containing
structures 139−140. Molecules with a small side chain like 129
are of special interest as highly aﬃne hH4R ligands. Sigmoidal
radioligand displacement curves at all HR subtypes are shown
for 58, which exhibited the highest H2R selectivity (Figure 4).
2.3.2. Functional Characterization at the hH2,3,4R
([35S]GTPγS Binding Assay). The compounds 5, 57−59, 61−
63, 136, and 139 were chosen to be investigated in the
Scheme 1. Synthesis of the Homodimeric (5, 53−60) and Heterodimeric (61−63) Histamine Receptor (HR) Ligandsa
aReagents and conditions: (a) diamine (1 equiv), 10 (2 equiv), dichloromethane (DCM), overnight, 0 °C → room temperature (rt); (b) K2CO3
(4.1 equiv), MeOH/H2O (7/3, v/v), 3−5 h, rt; (c) CH3I (2.1 equiv), MeCN, 1 h, reﬂux; (d) NEt3 (2 equiv), di-tert-butyl dicarbonate (Boc2O) (2
equiv), overnight, rt; (e) 6, 7, 8, or 9 (2 equiv), HgCl2 (2 equiv), NEt3 (6 equiv), DCM, overnight, rt; (f) equimolar mixtures (each 1 equiv) of 6 and
7, 6 and 8, or 7 and 8, HgCl2 (2 equiv), NEt3 (6 equiv), DCM, overnight, rt; (g) 20% TFA, DCM, overnight, reﬂux.
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[35S]GTPγS binding assay to determine their agonistic or
antagonistic activities at the hH2,3,4R (Table 2). All compounds
proved to be partial agonists at the hH2R and silent antagonists
at the hH3R and hH4R, except the monomeric ligands 136 and
139, which exhibited inverse agonistic activity at the hH3R and
the hH4R, respectively. The homodimeric ligand 58, containing
a C12-spacer, showed the highest H2R potency with a pEC50 of
7.27 and a maximal response of 52% relative to histamine. At
the H3R, the antagonistic activities of imidazole-containing
ligands (5, 57, 61, 62, and 136) were considerably higher than
those of compounds with an amino(methyl)thiazole moiety
(58, 59, 63, and 139) (e.g., pKB values of 57 and 59: 7.33 vs
4.05; Table 2). Antagonistic activities at the hH4R were
throughout low (pKB < 4).
2.3.3. H2R Species Selectivity. To study the H2R species
selectivity of the bisalkylguanidine-type dimeric ligands, the
agonistic activities of compounds 5, 57, 58, and 63 were also
investigated at the gpH2R and rH2R in the GTPγS binding
assay. The studied compounds exhibited slightly higher
agonistic potencies at the gpH2R and rH2R compared to the
Scheme 2. Synthesis of the Monomeric HR Ligands 127−141a
aReagents and conditions: (a) amine (1 equiv), 10 (1 equiv), MeCN, 2 h, 0 °C→ rt; (b) K2CO3 (2.1 equiv), MeOH/H2O (7/3, v/v), 3−5 h, rt; (c)
CH3I (1.1 equiv), MeCN, 1 h, reﬂux; (d) NEt3 (1 equiv), Boc2O (1 equiv), overnight, rt; (e) 6, 7, 8, or 9 (1 equiv), HgCl2 (2 equiv), NEt3 (3 equiv),
DCM, overnight, rt; (f) 20% TFA, DCM, overnight, reﬂux.
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hH2R, with pEC50 values >7.2 and >6.8, respectively (Table 3).
Compound 5 showed the highest gpH2R potency (pEC50 =
7.60) with a high eﬃcacy (Emax = 0.95), and 57 displayed the
highest rH2R potency (pEC50 = 7.61) with an eﬃcacy of 0.80.
In general, the eﬃcacies were considerably higher at the gpH2R
and rH2R (Emax > 0.7) compared to the hH2R (Emax < 0.52),
reaching full agonism in case of compound 63 (gpH2R, Emax =
1.02). In sum, these investigations revealed that the highest
potencies and eﬃcacies were observed at the gpH2R followed
by the rH2R and the hH2R.
2.3.4. Organ Bath Studies. In addition to the pharmaco-
logical characterization by radioligand competition binding (cf.
Table 1) and by functional studies using the [35S]GTPγS
binding assay (cf. Tables 2 and 3), organ bath experiments at
the guinea pig ileum (gpH1R) and at the spontaneously beating
guinea pig right atrium (gpH2R) were carried out. All ligands
(5, 53−63, 127−141, and 145) displayed antagonistic activities
at the gpH1R (Table 4). The imidazol-4-yl-type homodimeric
ligands 57 and the monomeric compound 137, containing a
dodecamethylene spacer and a decamethyl side chain,
respectively, showed the highest pA2 values (6.91 and 6.74,
respectively, cf. Table 4). A variation of the heteroaromatic
moieties did almost not aﬀect the pA2 value (gpH1R), as shown
for compounds containing a C8-spacer (5 and 58−63). The
experiments at the gpH2R provided interesting information
about the structure−activity relationship from monomeric and
dimeric HR ligands. Regarding the imidazole-containing ligands
(5, 53−57, and 127−138), longer alkyl spacers resulted in
higher agonistic potencies (e.g., pEC50 of 53 (C3-spacer) and
57 (C12-spacer): 7.31 vs 8.11, pEC50 of 127 (methyl) and 138
(dodecyl): 5.10 vs 6.63). By contrast, an inverse correlation was
observed for the dimeric compounds with respect to the
eﬃcacy: compound 53, containing a C3-spacer, acted nearly as a
full agonist (Emax = 0.96), and 57, containing a C12-chain,
exhibited a maximum response of 0.63 compared to histamine
(Table 4). With the aim of getting compounds of highest
potency and eﬃcacy, 58−63 were equipped with a C8-spacer
with 5 (pEC50 = 7.98, Emax = 0.91) as a prototype. The
replacement of imidazol-4-yl (5 and 138) by imidazol-1-yl (60
and 141) led to a drastic decrease in potency and eﬃcacy (5 vs
60: pEC50: 7.98 vs 5.31, Emax: 0.91 vs 0.20; 138 vs 141: pEC50:
6.63 vs not active, Emax: 0.91 vs 0). The introduction of
amino(methyl)thiazole moieties (58, 59, and 61−63) resulted
in potent gpH2R agonists (pEC50: 7.69−8.56, Emax: 0.78−1.02,
Table 4). Overall, a switch from monomeric to dimeric ligands
revealed compounds, which are approximately 100 times more
potent than their monomeric analogues. The concentration−
Scheme 3. Synthesis of N-[3-(1H-Imidazol-4-yl)propyl]-1,4,5,6-tetrahydropyrimidin-2-amine (145)a
aReagents and conditions: (a) tetrahydropyrimidine-2(1H)-thione (1 equiv), NaH (4.5 equiv), Boc2O (2.2 equiv), tetrahydrofuran (THF), hexane,
2 h, 0 °C → rt; (b) 6 (1 equiv), HgCl2 (2 equiv), NEt3 (3 equiv), DCM, overnight, rt; (c) 20% TFA, DCM, overnight, reﬂux.
Figure 3. RP-HPLC images of 57 (A) and 58 (B) after incubation in BB (pH 7.4) at rt for 12 months. Both compounds showed no decomposition.
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response curve (CRC) of 63 (atrium, gpH2R) is exemplarily
shown in Figure 5A.
The maximum response of all H2R agonists at the right
atrium could be completely antagonized by the addition of the
H2R antagonist cimetidine (pA2 = 6.10
25,26) (30 μM) after
cumulative organ stimulation (63, cf. Figure 5A). Full CRCs in
the presence of cimetidine (30 μM, 30 min preincubation)
were obtained for compounds 5, 57, 62, 63 (Figure 5B), 127,
128, 132, 135, and 137. The presence of cimetidine led to a
rightward shift of the CRCs in a way that is in accordance with
the calculated values via Schild equation (Table S1, Supporting
Information). These results proved that the positive chrono-
tropic eﬀect of the investigated (partial) agonists in the guinea
pig right atrium assay was mediated via the H2R.
2.4. Computational Studies. To determine accurate
binding modes of the most interesting bivalent compounds 5
and 58 at the hH2R, and of the monovalent ligand 129 at both
the hH3R and hH4R, molecular docking studies were
performed, coupled with molecular dynamics (MD) simu-
lations and free-energy (molecular mechanics generalized born
surface area (MM-GBSA)) calculations. Overall, ﬁve promising
binding poses for 5 and 58 at the hH2R, two poses for 129 at
the hH3R, and three poses for 129 at the hH4R were
determined by docking studies. Visual analysis of ligand−
receptor complexes reﬁned by molecular dynamics simulations
(30 ns) has shown that some poses primarily formed contacts
within the orthosteric binding site, whereas other poses
additionally interacted with residues of the allosteric site
between extracellular loop (ECL)2 and ECL3 (Figures S29−
S31 and Table S3). The binding free energies (MM-GBSA) of
the respective reﬁned lowest free-energy docking poses (pose
1) of 5 (hH2R), 58 (hH2R), 129 (hH3R), and 129 (hH4R)
amounted to −49.0, −61.5, −30.4, and −46.0 kcal/mol
(Figures 6, 7, and S28). Interestingly, compared to the other
poses, these lowest free-energy conformations were among
those with the strongest H-bond contacts between ligand atoms
and acidic amino acids of the orthosteric binding site (D983.32,
D1865.42 for 5 and 58 at hH2R, D114
3.32 for 129 at hH3R, and
Table 1. Binding Data (pKi Values) of Compounds Diphenhydramine (DPH), 1, 2, 5, 53−63, 127−141, and 145 Determined at
Human HxRs (x = 1−4)
a
hH1R
b hH2R
c hH3R
d hH4R
e
compound pKi N pKi N pKi N pKi N
DPH 7.62 ± 0.01 4 n.d.g n.d. n.d.
1 5.62 ± 0.0323 3 6.58 ± 0.04 48 7.59 ± 0.01 42 7.60 ± 0.01 45
2 <4 3 5.39 ± 0.04f 3 7.42 ± 0.04 3 8.13 ± 0.08 3
5 5.50 ± 0.01 2 7.05 ± 0.02 3 7.52 ± 0.01 3 7.06 ± 0.01 3
53 <5 2 6.76 ± 0.03 3 6.95 ± 0.02 3 6.70 ± 0.01 3
54 <5 2 6.39 ± 0.02 3 6.84 ± 0.01 3 6.18 ± 0.04 3
55 <5.5 2 6.82 ± 0.04 3 7.28 ± 0.03 3 6.37 ± 0.02 3
56 5.90 ± 0.01 2 7.47 ± 0.12 3 7.72 ± 0.03 3 7.68 ± 0.04 3
57 6.45 ± 0.01 2 7.41 ± 0.03 3 7.79 ± 0.01 3 7.70 ± 0.01 3
58 <5.5 2 7.33 ± 0.05 3 5.25 ± 0.05 3 5.00 ± 0.05 3
59 <5 2 6.63 ± 0.03 3 4.96 ± 0.05 3 4.28 ± 0.02 3
60 <5 2 5.35 ± 0.03 3 5.56 ± 0.02 3 4.47 ± 0.03 3
61 <6 2 6.93 ± 0.04 3 7.49 ± 0.03 3 7.13 ± 0.04 3
62 <6 2 7.27 ± 0.04 3 7.43 ± 0.03 3 6.97 ± 0.05 3
63 <5.5 2 6.91 ± 0.04 3 5.40 ± 0.05 3 5.14 ± 0.04 3
127 <4.5 2 5.56 ± 0.07 3 6.81 ± 0.03 3 7.58 ± 0.07 3
128 <4.5 2 5.31 ± 0.05 3 7.03 ± 0.04 3 7.87 ± 0.01 3
129 <4.5 2 5.52 ± 0.05 3 7.21 ± 0.02 3 8.04 ± 0.05 3
130 <5 2 5.38 ± 0.07 3 7.04 ± 0.02 3 7.42 ± 0.01 3
131 <5 2 6.11 ± 0.06 3 7.21 ± 0.04 3 8.04 ± 0.02 3
132 <4.5 2 6.12 ± 0.05 3 7.18 ± 0.03 3 7.75 ± 0.03 3
133 <4 2 5.60 ± 0.10 3 6.43 ± 0.03 3 6.66 ± 0.06 3
134 <5 2 6.03 ± 0.06 3 7.04 ± 0.02 3 8.17 ± 0.04 3
135 <5 2 6.10 ± 0.06 3 6.94 ± 0.04 3 7.60 ± 0.01 3
136 <5.5 2 6.96 ± 0.07 3 6.97 ± 0.04 3 6.90 ± 0.01 3
137 5.70 ± 0.01 2 6.85 ± 0.09 3 7.50 ± 0.03 3 7.01 ± 0.03 3
138 5.53 ± 0.01 2 6.22 ± 0.01 3 7.53 ± 0.02 3 7.90 ± 0.03 3
139 <5.5 2 6.33 ± 0.04 2 5.69 ± 0.01 3 5.25 ± 0.03 3
140 <5.5 2 6.57 ± 0.03 2 4.85 ± 0.06 3 4.95 ± 0.05 3
141 <5.5 2 5.90 ± 0.01 2 5.19 ± 0.01 3 4.89 ± 0.06 3
145 <5 2 5.50 ± 0.02 2 6.73 ± 0.05 3 7.42 ± 0.01 3
aData represent mean values ± standard error of the mean (SEM) from at least two independent experiments (N), each performed in triplicate.
bRadioligand competition binding experiments performed with [3H]mepyramine (hH1R, Kd 4.5 nM, c = 5 nM) at membranes of Sf9 cells expressing
the hH1R + RGS4.
cRadioligand competition binding experiments performed with [3H]tiotidine (hH2R, Kd 19.7 nM, c = 10 nM) at membranes of
Sf9 cells expressing the hH2R + Gsαs.
dRadioligand competition binding experiments performed with [3H]Nα-methylhistamine (hH3R, Kd 8.6 nM, c
= 3 nM) at membranes of Sf9 cells expressing the hH3R + Gαi2 + Gβ1γ2.
eRadioligand competition binding experiments performed with
[3H]histamine (hH4R, Kd 16.0 nM, c = 15 nM) at membranes of Sf9 cells expressing the hH4R + Gαi2 + Gβ1γ2.
fDisplacement of [3H]UR-DE257
(hH2R, Kd 31.3 nM, c = 20 nM) instead of [
3H]tiotidine. gn.d. = not determined.
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D943.32, E1825.46 for 129 at hH4R) (cf. Figure S32). The
probability for an interaction with these residues is supported
by the fact that they were proven to act as key player in
aminergic GPCR activation and ligand binding,27−30 or to
account for receptor selectivity (D1865.42 at hH2R).
31
Interestingly, both 5 and 58 showed high binding aﬃnities at
hH2R (Ki < 100 nM), low aﬃnities at the hH1R (Ki > 1 μM),
but varying aﬃnities at the hH3R and hH4R (5: Ki < 100 nM;
58: Ki > 1 μM). Although, by contrast, the monomeric
imidazole-type analogue 129 bound unexpectedly poor to the
hH2R, and, comparable to the dimeric compounds, also to the
hH1R (Ki > 1 μM), it bound to the hH3R and hH4R with high
aﬃnity (Ki < 100 nM). In this context, an amino(methyl)-
thiazole moiety present in 58, unlike an imidazole moiety
present in 5 or 129, was shown to trigger hH2R selectivity also
in the case of other ligands.32,33 Aiming at an attempt to explain
this behavior, diﬀerent steric eﬀects of amino acids enclosing
the orthosteric binding pocket may come into play due to less
voluminous residues at the hH2R (V99
3.33, V176ECL2.54-
Q177ECL2.55) compared to hH1R (Y108
3.33, F184ECL2.54-
Y185ECL2.55), hH3R (Y115
3.33, F192ECL2.54-F193ECL2.55), and
hH4R (Y95
3.33, F168ECL2.54-F169ECL2.55). In addition, an absence
(hH1R) or diﬀerent locations (hH3R: E206
5.46; hH4R: E182
5.46)
of fundamental acidic amino acids in TM5 compared to hH2R
(D1865.42) may further contribute to hH2R selectivity of
amino(methyl)thiazole-type compounds, but to preferential
binding of imidazole-type ligands, such as 5 or 129, to the
hH3R and hH4R. Although 5 is still capable of binding to hH2R,
most probably due to its larger and more ﬂexible chain, 129
merely binds to the hH3R and hH4R with high aﬃnity in a well-
deﬁned binding mode. Noteworthy, the lowest free-energy pose
(pose 1) of 129 bound to the hH4R showed H-bond contacts
with E163ECL2 and T1785.42 in addition to contacts with D943.32
and E1825.46, compared to relatively few and weak H-bond
interactions when bound to hH3R (Figures 7 and S32). This
may contribute to a lower 129 binding free energy when bound
to the hH4R, compared to hH3R (Figure S28).
3. SUMMARY AND CONCLUSIONS
Homo- (5 and 53−60) and heterodimeric (61−63) as well as
monomeric (127−141 and 145) hetarylpropylguanidine-type
HR ligands were obtained in excellent yield by a six-step
synthesis. The replacement of the imidazolyl by an amino-
thiazolyl moiety led, in accordance with previous reports on
acylguanidine- and carbamoylguanidine-type HR ligands,9,10,22
to highly selective and potent H2R agonists. The variation of
the spacer length revealed best results for compounds
containing a C8-, C10-, or C12-spacer (5, 56−59, and 61−63).
The heterodimeric compounds showed potencies in a one-digit
nanomolar range (up to 250 times the potency of histamine) as
full agonists in the gpH2R atrium assay. In comparison to the
monomeric ligands, the dualsteric structures showed up notably
higher hH2R selectivity, higher aﬃnities in the hH2R binding
assay, and higher potencies at the functional H2R assays (e.g.,
guinea pig right atrium). The dimeric ligands displayed a
slightly higher sensitivity for gpH2R and rH2R compared to the
Figure 4. Radioligand displacement curves from radioligand
competition binding experiments performed with compound 58 and
[3H]mepyramine (hH1R, Kd 4.5 nM, c = 5 nM), [
3H]tiotidine (hH2R,
Kd 19.7 nM, c = 10 nM), [
3H]Nα-methylhistamine (hH3R, Kd 8.6 nM,
c = 3 nM), or [3H]histamine (hH4R, Kd 16.0 nM, c = 15 nM) at
membranes of Sf9 cells expressing the respective hHR. Data represent
mean values ± SEM from at least two independent experiments, each
performed in triplicate.
Table 2. Agonistic (pEC50) and Antagonistic (pKB) Activities of 1, 2, 5, 57−59, 61−63, 136, and 139 at the hH2,3,4R Determined
in the [35S]GTPγS Binding Assaya
hH2R
b hH3R
c hH4R
d
compound pEC50
e Emax
f N pEC50
e (pKB)
g Emax
f N pEC50
e (pKB)
g Emax
f N
1 6.01 ± 0.07 1.00 7 8.52 ± 0.10 1.00 6 8.20 ± 0.08 1.00 3
2 5.59 ± 0.01h,24 0.66 ± 0.02h,24 3 8.12 ± 0.10h,24 0.69 ± 0.04h,24 3 8.09 ± 0.04h,24 0.83 ± 0.01h,24 3
5 6.78 ± 0.01 0.50 ± 0.03 6 (6.87 ± 0.05) 0 3 (3.39 ± 0.02) 0 3
57 7.27 ± 0.05 0.52 ± 0.03 6 (7.33 ± 0.07) 0 3 (3.49 ± 0.01) 0 3
58 6.61 ± 0.03 0.33 ± 0.03 5 (4.53 ± 0.05) 0 3 (3.83 ± 0.03) 0 3
59 6.53 ± 0.08 0.40 ± 0.05 3 (4.05 ± 0.10) 0 3 (3.58 ± 0.05) 0 3
61 6.23 ± 0.09 0.54 ± 0.05 3 (7.18 ± 0.02) 0 3 (3.69 ± 0.02) 0 3
62 6.51 ± 0.03 0.45 ± 0.04 3 (7.09 ± 0.01) 0 3 (3.43 ± 0.01) 0 3
63 6.60 ± 0.02 0.47 ± 0.03 6 (4.67 ± 0.05) 0 3 (3.73 ± 0.03) 0 3
136 6.86 ± 0.08 0.48 ± 0.02 3 7.54 ± 0.06 −0.53 ± 0.03 3 (3.68 ± 0.01) 0 3
139 5.16 ± 0.03 −0.43 ± 0.01 3 (5.37 ± 0.04) 0 3 4.86 ± 0.03 −0.97 ± 0.01 3
aData represent mean values ± SEM from at least three independent experiments (N), each performed in triplicate. Data were analyzed by nonlinear
regression and were best-ﬁtted to sigmoidal concentration−response curves (CRCs). b[35S]GTPγS binding assay at membranes of Sf9 cells
expressing the hH2R + Gsαs.
c[35S]GTPγS binding assay at membranes of Sf9 cells expressing the hH3R + Gαi2 + Gβ1γ2.
d[35S]GTPγS binding assay
at membranes of Sf9 cells expressing the hH4R + Gαi2 + Gβ1γ2.
epEC50: −log EC50.
fEmax: maximal response relative to histamine (Emax = 1.00).
gFor
determination of antagonism, reaction mixtures contained histamine (1) (100 nM), and ligands were at concentrations from 10 nM to 1 mM; pKB =
−log KB. hDetermined in a steady-state [32P]GTPase assay on Sf9 cells expressing the related receptors.
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hH2R (maximum deviation less than 1 log unit). Monomeric
imidazole-type compounds with small side chains, like 129,
showing high hH4R aﬃnity, could be of interest for the
development of selective hH4R ligands to play an important
role in diﬀerent inﬂammatory, allergic, and immunological
processes.34,35 Molecular modeling studies, including the
bivalent ligands 5 and 58, suggested an interaction of the
guanidine groups with the acidic residues D983.32 and D1865.42
as key contributions to H2R binding. As the bisalkylguanidines
turned out to be very stable chemical entities, the synthesized
H2R selective aminothiazole derivatives represent promising
lead structures for the development of pharmacological tools
for the H2R, such as 58, 59, and 63. Moreover, the presented
data could be of interest for the development of CNS
penetrating H2R agonistsin consideration of changing the
basicity of the strongly basic alkylguanidine structure, using
Table 3. Agonistic Activities of 1, 5, 57, 58, and 63 at the h/gp/rH2R Determined in the [
35S]GTPγS Binding Assaya
hH2R
b,g gpH2R
c rH2R
d
compound pEC50
e Emax
f N pEC50
e Emax
f N pEC50
e Emax
f N
1 6.01 ± 0.07 1.00 7 5.82 ± 0.02 1.00 3 5.97 ± 0.02 1.00 3
5 6.78 ± 0.01 0.50 ± 0.03 6 7.60 ± 0.02 0.95 ± 0.05 3 7.18 ± 0.07 0.80 ± 0.01 3
57 7.27 ± 0.05 0.52 ± 0.03 6 7.53 ± 0.03 0.89 ± 0.07 3 7.61 ± 0.10 0.80 ± 0.03 3
58 6.61 ± 0.03 0.33 ± 0.03 5 7.28 ± 0.05 0.97 ± 0.06 3 6.83 ± 0.09 0.70 ± 0.04 3
63 6.60 ± 0.02 0.47 ± 0.03 6 7.33 ± 0.03 1.02 ± 0.04 3 6.85 ± 0.07 0.87 ± 0.02 3
aData represent mean values ± SEM from at least three independent experiments (N), each performed in triplicate. Data were analyzed by nonlinear
regression and were best-ﬁtted to sigmoidal CRCs. b[35S]GTPγS binding assay at membranes of Sf9 cells expressing the hH2R + Gsαs.
c[35S]GTPγS
binding assay at membranes of Sf9 cells expressing the gpH2R + Gsαs.
d[35S]GTPγS binding assay at membranes of Sf9 cells expressing the rH2R +
Gsαs.
epEC50: −log EC50.
fEmax: maximal response relative to histamine (Emax = 1.00).
gData taken from Table 2.
Table 4. Agonistic (pEC50) and Antagonistic (pA2) Activities of 1, 2, 5, 53−63, 127−141, and 145 Determined by Organ Bath
Studies at the gpH1R (Ileum) and the gpH2R (Atrium)
a
gpH1R gpH2R
compound pA2
b (pEC50) N pEC50
c,d Emax
e N
1 (6.68 ± 0.03) 255 6.16 ± 0.01 1.00 225
2 n.a.f 24 5.16 ± 0.04 0.75 ± 0.03 5
5 5.77 ± 0.04 9 7.98 ± 0.05 0.91 ± 0.05 3
53 6.20 ± 0.03 9 7.31 ± 0.03 0.96 ± 0.01 3
54 5.89 ± 0.03 9 7.42 ± 0.07 0.94 ± 0.01 3
55 5.69 ± 0.04 9 7.78 ± 0.04 0.90 ± 0.04 3
56 6.64 ± 0.05 8 7.60 ± 0.08 0.71 ± 0.04 3
57 6.91 ± 0.04 9 8.11 ± 0.08 0.63 ± 0.03 3
58 5.88 ± 0.03 9 8.38 ± 0.05 0.78 ± 0.01 3
59 6.08 ± 0.03 9 7.69 ± 0.06 0.94 ± 0.03 3
60 5.37 ± 0.05 9 5.31 ± 0.06 0.20 ± 0.02 3
61 5.85 ± 0.04 6 7.99 ± 0.05 0.91 ± 0.03 3
62 6.01 ± 0.05 6 8.25 ± 0.06 1.02 ± 0.06 3
63 6.00 ± 0.04 6 8.56 ± 0.06 0.88 ± 0.03 3
127 4.23 ± 0.02 4 5.10 ± 0.06 0.58 ± 0.07 3
128 5.08 ± 0.03 10 5.14 ± 0.05 0.55 ± 0.07 3
129 4.83 ± 0.05 8 5.40 ± 0.11 0.83 ± 0.03 3
130 5.27 ± 0.04 10 5.81 ± 0.08 0.87 ± 0.04 3
131 5.39 ± 0.04 11 6.08 ± 0.12 0.86 ± 0.04 3
132 4.99 ± 0.03 14 5.87 ± 0.05 0.86 ± 0.08 3
133 n.d.g 0 4.82 ± 0.09 0.92 ± 0.03 3
134 5.35 ± 0.04 12 6.44 ± 0.11 0.90 ± 0.02 3
135 5.14 ± 0.03 19 6.62 ± 0.07 0.89 ± 0.05 3
136 6.10 ± 0.06 8 6.71 ± 0.10 1.13 ± 0.07 3
137 6.74 ± 0.05 12 6.53 ± 0.08 0.90 ± 0.03 3
138 6.71 ± 0.05 12 6.63 ± 0.07 0.91 ± 0.03 3
139 6.36 ± 0.06 6 6.57 ± 0.07 0.60 ± 0.02 3
140 6.43 ± 0.07 6 6.25 ± 0.07 0.70 ± 0.01 3
141 6.43 ± 0.06 6 n.a. 0 3
145 5.24 ± 0.04 9 5.82 ± 0.07 1.00 ± 0.03 3
aData represent mean values ± SEM from at least three independent experiments (N). Data were analyzed by nonlinear regression and were best-
ﬁtted to sigmoidal CRCs. bpA2: −log c(Ant) + log(r − 1); r = 10ΔpEC50; ΔpEC50 was calculated from pEC50 of histamine and pEC50 of histamine in
the presence of the respective antagonist. cpEC50: −log EC50. dpEC50 was calculated from the mean-corrected shift ΔpEC50 of the agonist curve
relative to the histamine reference curve by equation pEC50 = 6.16 + ΔpEC50.
eEmax: maximal response relative to the maximal increase in heart rate
induced by histamine (Emax = 1.00).
fn.a. = not active. gn.d. = not determined.
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bioisosteric approaches, and the lipophilicityand H2R ligands
useful for the treatment of acute myeloid leukemia.
Figure 5. CRCs of histamine (reference) and 63 in the absence (A) and presence (B) of 30 μM cimetidine at the gpH2R (atrium). Displayed curves
were calculated by endpoint determination (N = 1).
Figure 6. Most probable binding mode of 5 (A) and 58 (B) at the hH2R, showing the respective most predominant clustered structure with the
lowest binding free energy of the docking poses investigated by 30 ns MD simulations. Fundamental amino acids involved in ligand binding are
shown as light-blue sticks, 5 is colored in green and 58 in magenta. H-bond contacts are illustrated as dashed yellow lines. The allosteric binding site
is located most likely between ECL2 and ECL3.
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4. EXPERIMENTAL SECTION
4.1. General Conditions. Commercially available chem-
icals (9, 10, 11−16, 64−69, and 82−87) and solvents were
purchased from Acros Organics (Geel, Belgium), Alfa Aesar
GmbH & Co. KG (Karlsruhe, Germany), Iris Biotech GmbH
(Marktredwitz, Germany), Merck KGaA (Darmstadt, Ger-
many), Sigma-Aldrich Chemie GmbH (München, Germany),
or TCI Europe (Zwijndrecht, Belgium) and were used as
received. Deuterated solvents for nuclear magnetic resonance
(1H NMR and 13C NMR) spectra were purchased from
Deutero GmbH (Kastellaun, Germany). Compounds 6−8 were
prepared as previously described.22,32,36,37 The synthesis steps
described in Section 2.1 were carried out according to reported
procedures.8,17−19 All reactions involving dry solvents were
accomplished in dry ﬂasks under nitrogen or argon atmosphere.
Millipore water was used for the preparation of buﬀers, HPLC
eluents, and stock solutions. Column chromatography was
carried out using Merck silica gel Geduran 60 (0.063−0.200
mm) or Merck silica gel 60 (0.040−0.063 mm) (ﬂash column
chromatography). The reactions were monitored by thin-layer
chromatography (TLC) on Merck silica gel 60 F254 aluminum
sheets, and spots were visualized under UV light at 254 nm, by
iodine vapor, ninhydrin, or fast blue B staining.
Nuclear magnetic resonance (1H NMR and 13C NMR)
spectra were recorded on a Bruker (Karlsruhe, Germany)
Avance 300 (1H: 300 MHz, 13C: 75 MHz) or Avance 400 (1H:
400 MHz, 13C: 101 MHz) spectrometer using perdeuterated
solvents. The chemical shift δ is given in parts per million
(ppm). Multiplicities were speciﬁed with the following
abbreviations: s (singlet), d (doublet), t (triplet), q (quartet),
quint (quintet), m (multiplet), and br (broad signal) as well as
combinations thereof. 13C NMR peaks were determined by
distortionless enhancement by polarization transfer (DEPT)
135 and DEPT 90: “+” primary and tertiary carbon atom
(positive DEPT 135 signal), “−” secondary carbon atom
(negative DEPT 135 signal), and “quat” quaternary carbon
atom. NMR spectra were processed with MestReNova 11.0
Figure 7. Most probable binding modes of 129 at both the hH3R (A) and hH4R (B), showing the respective most predominant clustered structure
with the lowest binding free energy of the docking poses investigated by 30 ns MD simulations. Fundamental amino acids involved in ligand binding
are shown as light-blue sticks, 129 is colored in cyan when bound to the hH3R (A) and in orange when bound to the hH4R (B). H-bond contacts are
illustrated as dashed yellow lines. The allosteric binding site is located most likely between ECL2 and ECL3 in both cases.
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(Mestrelab Research, Compostela, Spain). High-resolution
mass spectrometry (HRMS) was performed on an Agilent
6540 UHD Accurate-Mass quadrupole time-of-ﬂight liquid
chromatography/mass spectrometry (MS) system (Agilent
Technologies, Santa Clara, CA) using an electrospray
ionization (ESI) source. Elemental analyses (EA) were
performed on a Heraeus Elementar Vario EL III and are
within ±0.4% unless otherwise noted. Melting points (mp)
were measured on a Büchi (Essen, Germany) B-545 apparatus
using an open capillary and are uncorrected. Preparative HPLC
was performed with a system from Knauer (Berlin, Germany)
consisting of two K-1800 pumps and a K-2001 detector. A
Eurospher-100 C18 (250 × 32 mm2, 5 μm) (Knauer, Berlin,
Germany) or a Kinetex XB-C18 (250 × 21.2 mm2, 5 μm)
(Phenomenex, Aschaﬀenburg, Germany) served as stationary
phase. As mobile phase, 0.1% TFA in millipore water and
acetonitrile (MeCN) were used. The temperature was 25 °C,
the ﬂow rate was 15 mL/min, and UV detection was performed
at 220 nm. Analytical HPLC was performed on system from
Merck-Hitachi (Darmstadt/Düsseldorf, Germany) composed
of an L-6200-A pump, an AS 2000A autosampler, an L-4000A
UV detector, and a D-6000 interface. Stationary phase was a
Eurosphere-110 C18 (250 × 4 mm2, 5 μm) (Knauer, Berlin,
Germany) or a Kinetex XB-C18 (250 × 4.6 mm2, 5 μm)
(Phenomenex, Aschaﬀenburg, Germany). As mobile phase,
mixtures of MeCN and aqueous TFA were used (linear
gradient: MeCN/TFA (0.1%) (v/v) 0 min: 5:95, 25 min:
50:50, 26−35 min: 95:5 (method A); 0 min: 10:90, 25 min:
50:50, 26−35 min: 95:5 (method B); ﬂow rate = 0.80 mL/min,
t0 = 3.32 min). Capacity factors were calculated according to k
= (tR − t0)/t0. Detection was performed at 220 nm. All
compounds were analyzed using method A, except for 139−
141 (method B). Furthermore, ﬁltration of the stock solutions
with poly(tetraﬂuoroethylene) ﬁlters (25 mm, 0.2 μm,
Phenomenex Ltd., Aschaﬀenburg, Germany) was accomplished
before testing. Compound purities determined by HPLC were
calculated as the peak area of the analyzed compound in %
relative to the total peak area (UV detection at 220 nm). The
HPLC purities (see Supporting Information) of the ﬁnal
compounds were ≥95% except for compound 58 (94.3%). The
tested compounds were screened for pan-assay interference
compounds (PAINS) and aggregation by publicly available
ﬁlters (http://zinc15.docking.org/patterns/home, http://
advisor.docking.org).38,39 None of the screened structures
have been previously reported as PAINS or an aggregator.
Since Devine et al. described 2-aminothiazoles as a promiscu-
ous frequent hitting scaﬀold at diﬀerent enzymes,40 full dose−
response curves for all experiments and compounds, not only
for the 2-aminothiazoles, were measured. None of the curves
showed abnormalities, e.g., high Hill slopes, which could be a
hint for PAINS.39
4.2. Chemical Synthesis and Analytical Data.
4.2.1. General Procedure for the Synthesis of the
Dibenzoylthioureas 17−22. To an ice-cold solution of the
pertinent diamine (11−16, 1 equiv) in dichloromethane
(DCM), benzoyl isothiocyanate (2 equiv) in DCM was
added dropwise. The reaction was allowed to stir at room
temperature (rt) overnight, and the organic solvent was
concentrated under vacuum. The residue was suspended in
80 mL of methanol (MeOH) for 1 h and ﬁltered to give the
pure title compound.
4.2.1.1. N,N′-{[Octane-1,8-diylbis(azanediyl)]bis-
[carbonothioyl]}dibenzamide (20). The title compound was
prepared from octane-1,8-diamine (14, 1.08 g, 7.50 mmol) and
10 (2.02 mL, 15.00 mmol) in DCM (30 mL) according to the
general procedure (Rf = 0.40 in ethyl acetate (EtOAc)/Hex
1:3). The product was obtained as a yellow solid (3.30 g, 93%),
mp 146.8 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 10.74
(brs, 2H), 9.00 (brs, 2H), 7.88−7.78 (m, 4H), 7.68−7.57 (m,
2H), 7.56−7.45 (m, 4H), 3.71 (q, J = 7.2 Hz, 4H), 1.72 (quint,
J = 6.7 Hz, 4H), 1.54−1.29 (m, 8H). 13C NMR (75 MHz,
CDCl3) δ (ppm) 179.7, 166.9, 133.6, 131.8, 129.2, 127.4, 45.9,
29.1, 28.2, 26.8. HRMS (ESI-MS): m/z [M + H+] calculated
for C24H31N4O2S2
+: 471.1883, found 471.1884, C24H30N4O2S2
(470.65).
4.2.2. General Procedure for the Synthesis of the
Bisthioureas 23−28. The corresponding dibenzoylthiourea
(17−22, 1 equiv) was stirred in a solution of K2CO3 (4.1
equiv) in MeOH/H2O (7/3 v/v) for 3−5 h at rt. The
proportion of MeOH was evaporated, and the resulting
suspension was stirred for 1 h. The pure product was ﬁltered
with a Büchner funnel.
Because of the thione−thiol tautomerism, a splitting of the
NH−CH2−(CH2)x−CH2−NH signal could be observed in the
following NMR spectra. Two broad singlets could be noted
right next to each other. In each case, the integration value was
exactly 4. For all of the other symmetric CH2 peaks, this peak
splitting was not shown.
4.2.2.1. 1,1′-(Octane-1,8-diyl)bis(thiourea) (26).41 The title
compound was prepared from 20 (3.30 g, 7.01 mmol) and
K2CO3 (3.88 g, 28.75 mmol) in MeOH/H2O (7/3 v/v, 100
mL) according to the general procedure (Rf = 0.43 in DCM/
MeOH/NH3 90:10:0.1), yielding a colorless solid (1.80 g,
98%), mp 187.2 °C. 1H NMR (300 MHz, dimethyl sulfoxide
(DMSO)-d6) δ (ppm) 7.60 (brs, 2H), 6.88 (brs, 4H), 3.32 +
3.00 (2 brs, 2.4H + 1.6H (thione−thiol tautomerism)), 1.43
(quint, J = 6.9 Hz, 4H), 1.31−1.20 (m, 8H). 13C NMR (75
MHz, DMSO-d6) δ (ppm) 182.9, 41.3, 32.7, 28.7, 26.2. HRMS
(ESI-MS): m/z [M + H+] calculated for C10H23N4S2
+:
263.1359, found 263.1359; C10H22N4S2 (262.44).
4.2.3. General Procedure for the Synthesis of the Bis-S-
methylisothioureas (29−34). The appropriate bisthiourea
(23−28, 1 equiv) was dissolved in 50 mL of acetonitrile
(MeCN) and treated with methyl iodide (2.1 equiv). The
reaction mixture was stirred for 1 h under reﬂuxing and the
solvent was evaporated under vacuum. The resulting product
(di-HI salt) was washed three times with 20 mL of diethylether
(Et2O) and dried under vacuum.
4.2.3.1. 1,1′-(Octane-1,8-diyl)bis(S-methylisothiourea)
(32). The compound 26 (1.80 g, 6.86 mmol) was dissolved
in MeCN (50 mL) and treated with methyl iodide (0.90 mL,
14.40 mmol) according to the general procedure (Rf = 0.16 in
DCM/MeOH/NH3 90:10:0.1). The resulting product was
obtained as a yellow oil (32·2HI, 3.70 g, 99%). 1H NMR (300
MHz, CD3OD, hydrogen iodide) δ (ppm) 3.38 (t, J = 7.2 Hz,
4H), 2.65 (s, 6H), 1.66 (quint, J = 7.2 Hz, 4H), 1.44−1.36 (m,
8H). 13C NMR (75 MHz, CD3OD, hydrogen iodide) δ (ppm)
170.0, 45.5, 30.2, 29.0, 27.7, 14.4. HRMS (ESI-MS): m/z [M +
H+] calculated for C12H27N4S2
+: 291.1672, found 291.1674;
C12H26N4S2·2HI (546.32).
4.2.4. General Procedure for the Synthesis of the Bis-N′-
boc-S-methylisothioureas (35−40). To a solution of the
pertinent isothiourea (29−34) and 2 equiv of triethylamine
(NEt3) in 50 mL of DCM, a solution of Boc2O (2 equiv) in 20
mL of DCM was added dropwise at rt. The reaction mixture
was stirred overnight (rt) and washed with H2O and a saturated
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solution of NaCl. The organic layer was dried over Na2SO4, and
the crude product was puriﬁed by column chromatography
(EtOAc/petroleum ether (PE) 1/4−1/2 v/v).
4.2.4.1. 1,1′-(Octane-1,8-diyl)bis(N′-tert-butoxycarbonyl-
S-methylisothiourea) (38). The reaction was carried out with
32 (3.70 g, 6.77 mmol), NEt3 (1.88 mL, 13.55 mmol), and
Boc2O (2.96 g, 13.55 mmol) according to the general
procedure (Rf = 0.62 in EtOAc/Hex 1:2), yielding a colorless
oil (3.30 g, 99%). 1H NMR (300 MHz, CDCl3) δ (ppm) 9.56
(brs, 2H), 3.28 (q, J = 7.0 Hz, 4H), 2.45 (s, 6H), 1.65−1.56 (m,
4H), 1.49 (s, 18H), 1.38−1.30 (m, 8H). 13C NMR (75 MHz,
CDCl3) δ (ppm) 173.5, 162.3, 79.2, 43.8, 29.3, 29.0, 28.3, 26.7,
13.6. HRMS (ESI-MS): m/z [M + H+] calculated for
C22H43N4O4S2
+: 491.2720, found 491.2721; C22H42N4O4S2
(490.72).
4.2.5. General Procedure for the Guanidinylation Reaction
of 41−49. To a suspension of the corresponding amine 6, 7, 8,
or 9 (2 equiv), the pertinent bis-N′-boc-S-methylisothiourea
35−40 (1 equiv), and HgCl2 (2 equiv) in DCM, NEt3 (6
equiv) was added. The mixture was stirred overnight at rt. A
possible excess of HgCl2 was quenched with 7 N NH3 in
MeOH (3−5 mL). The resulting suspension was ﬁltered over
Celite, and the crude product was puriﬁed by column
chromatography (DCM/MeOH/7 N NH3 in MeOH 98/1/
1−95/3/2 v/v/v).
4.2.5.1. 1,1′-(Octane-1,8-diyl)bis{N″-tert-butoxycarbonyl-
N′-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine} (44). The
title compound was synthesized from 6 (500 mg, 1.36 mmol),
38 (334 mg, 0.68 mmol), HgCl2 (369 mg, 1.36 mmol), and
NEt3 (0.57 mL, 4.08 mmol) in DCM (20 mL) according to the
general procedure (Rf = 0.27 in DCM/MeOH/NH3 98:2:0.1).
The product was obtained as a yellow oil (460 mg, 60%). 1H
NMR (300 MHz, CDCl3) δ (ppm) 9.05 (brs, 2H), 7.38−7.19
(m, 20H), 7.15−7.01 (m, 12H), 6.53 (d, J = 1.4 Hz, 2H), 3.46−
3.02 (m, 8H), 2.55 (t, J = 6.4 Hz, 4H), 1.84 (quint, J = 6.8 Hz,
4H), 1.44 (m + s, 4 + 18H), 1.22−1.12 (m, 8H). 13C NMR (75
MHz, CDCl3) δ (ppm) 164.4, 160.5, 142.3, 140.6, 138.0, 129.7,
128.1, 128.1, 118.3, 77.5, 75.2, 41.4, 40.7, 29.2, 28.8, 28.7, 28.6,
26.9. HRMS (ESI-MS): m/z [M + H+] calculated for
C70H85N10O4
+: 1129.6750, found 1129.6737; C70H84N10O4
(1129.51).
4.2.5.2. 1,1′-(Octane-1,8-diyl)bis{N″-tert-butoxycarbonyl-
N′-[(2-tert-butoxycarbonyl-amino-4-methylthiazol-5-yl)-
propyl]guanidine} (47). The title compound was synthesized
from 7 (554 mg, 2.04 mmol), 38 (500 mg, 1.02 mmol), HgCl2
(554 mg, 2.04 mmol), and NEt3 (0.85 mL, 6.12 mmol) in
DCM (20 mL) according to the general procedure (Rf = 0.28
in DCM/MeOH/NH3 98:2:0.1). The product was obtained as
a yellow foamlike solid (520 mg, 54%). 1H NMR (300 MHz,
CDCl3) δ (ppm) 11.28 (brs, 2H), 3.24−3.06 (m, 8H), 2.67 (t, J
= 6.5 Hz, 4H), 2.17 (s, 6H), 1.82 (quint, J = 7.3 Hz, 4H), 1.44
(s, 18H), 1.39 (m + s, 4 + 18H), 1.23−1.16 (m, 8H). 13C NMR
(75 MHz, CDCl3) δ (ppm) 164.2, 160.0, 158.3, 152.9, 142.1,
122.9, 82.2, 77.9, 41.1, 40.3, 30.7, 29.1, 29.0, 28.4, 28.3, 26.7,
23.3, 14.5. HRMS (ESI-MS): m/z [M + H+] calculated for
C44H77N10O8S2
+: 937.5362, found 937.5367; C44H76N10O8S2
(937.27).
4.2.6. General Procedure for the Guanidinylation Reaction
of 50−52. To a suspension of the corresponding amine 6, 7, or
8 (two out of them, each 1 equiv), 38 (1 equiv), and HgCl2 (2
equiv) in DCM, NEt3 (6 equiv) was added. The mixture was
stirred overnight at rt. A possible excess of HgCl2 was quenched
with 7 N NH3 in MeOH (3−5 mL). The resulting suspension
was ﬁltered over Celite, and the crude product was used in the
next step without further puriﬁcation.
4.2.6.1. 2-tert-Butoxycarbonyl-1-[3-(2-tert-butoxycarbon-
yl-amino-4-methylthiazol-5-yl)propyl]-3-{8-[2-tert-butoxy-
carbonyl-3-(3-(2-tert-butoxycarbonylaminothiazol-5-yl)-
propyl)guanidino]octyl}guanidine (52). The title compound
was synthesized from 7 (111 mg, 0.41 mmol), 8 (105 mg, 0.41
mmol), 38 (200 mg, 0.41 mmol), HgCl2 (222 mg, 0.82 mmol),
and NEt3 (0.17 mL, 1.22 mmol) in DCM (20 mL) according to
the general procedure. The crude product was used in the next
step without further puriﬁcation. HRMS (ESI-MS): m/z [M +
H+] calculated for C43H75N10O8S2
+: 923.5204, found 923.5208;
C43H74N10O8S2 (923.25).
4.2.7. General Procedure for the Synthesis of the Bivalent
Ligands (5 and 53−63). TFA (4.0 mL) was added to a
solution of the protected precursors 41−52 in DCM (16.0 mL,
20% TFA in DCM), and the mixture was reﬂuxed overnight
until the protecting groups were removed (TLC control).
Subsequently, the solvent was evaporated in vacuo and the
residue was washed three times with Et2O (each 20 mL). The
crude product was puriﬁed by preparative RP-HPLC (MeCN/
0.1% TFA (aq): 5/95−40/60). All compounds were dried by
lyophilization and obtained as tetra-triﬂuoroacetates.
4.2.7.1. 1,1′-(Octane-1,8-diyl)bis{3-[3-(1H-imidazol-4-yl)-
propyl]guanidine} (5).13 Prepared from 44 (280 mg, 0.25
mmol) in DCM (16.0 mL) and TFA (4.0 mL) according to the
general procedure, 5 was yielded as a yellow oil (150 mg, 67%):
RP-HPLC: 98%, (tR = 13.97, k = 3.21).
1H NMR (300 MHz,
CD3OD, tetra-triﬂuoroacetate) δ (ppm) 8.83 (d, J = 1.2 Hz,
2H), 7.39 (s, 2H), 3.28 (t, J = 7.5 Hz, 4H), 3.20 (t, J = 7.0 Hz,
4H), 2.83 (t, J = 7.8 Hz, 4H), 1.98 (quint, J = 7.4 Hz, 4H), 1.59
(quint, J = 6.9 Hz, 4H), 1.42−1.35 (m, 8H). 13C NMR (75
MHz, CD3OD, tetra-triﬂuoroacetate) δ (ppm) 163.1 (q, J =
35.2 Hz), 157.6, 154.3, 134.9, 134.5, 117.1, 42.7, 41.7, 30.3,
30.0, 28.9, 27.7, 22.6. HRMS (ESI-MS): m/z [M + H+]
calculated for C22H41N10
+: 445.3510, found 445.3506;
C22H40N10·4TFA (900.72).
4.2.7.2. 1,1′-(Dodecane-1,12-diyl)bis{3-[3-(1H-imidazol-4-
yl)propyl]guanidine} (57). Prepared from 46 (240 mg, 0.20
mmol) in DCM (16.0 mL) and TFA (4.0 mL) according to the
general procedure, 57 was yielded as a yellow oil (120 mg,
62%): RP-HPLC: 99%, (tR = 17.84, k = 4.37).
1H NMR (300
MHz, CD3OD, tetra-triﬂuoroacetate) δ (ppm) 8.77 (d, J = 1.3
Hz, 2H), 7.32 (d, J = 0.9 Hz, 2H), 3.27 (t, J = 7.0 Hz, 4H), 3.17
(t, J = 7.1 Hz, 4H), 2.80 (t, J = 7.7 Hz, 4H), 1.95 (quint, J = 7.3
Hz, 4H), 1.56 (quint, J = 6.8 Hz, 4H), 1.34−1.26 (m, 16H).
13C NMR (75 MHz, CD3OD, tetra-triﬂuoroacetate) δ (ppm)
163.1 (q, J = 34.8 Hz), 157.6, 157.6, 134.8, 134.6, 129.0 (q, J =
44.3 Hz), 117.0, 42.7, 41.6, 30.7, 30.7, 30.4, 30.0, 28.9, 27.8,
22.6. HRMS (ESI-MS): m/z [M + H+] calculated for
C26H49N10
+: 501.4136, found 501.4131; C26H48N10·4TFA
(956.83).
4.2.7.3. 1,1′-(Octane-1,8-diyl)bis{3-[3-(2-amino-4-methyl-
thiazol-5-yl)propyl]guanidine} (58). Prepared from 47 (520
mg, 0.55 mmol) in DCM (16.0 mL) and TFA (4.0 mL)
according to the general procedure, 58 was yielded as a yellow
oil (280 mg, 51%): RP-HPLC: 94%, (tR = 15.53, k = 3.68).
1H
NMR (300 MHz, CD3OD, tetra-triﬂuoroacetate) δ (ppm)
3.26−3.10 (m, 8H), 2.71 (t, J = 7.1 Hz, 4H), 2.20 (s, 6H), 1.86
(quint, J = 7.3 Hz, 4H), 1.61−1.52 (m, 4H), 1.37−1.30 (m,
8H). 13C NMR (75 MHz, CD3OD, tetra-triﬂuoroacetate) δ
(ppm) 170.4, 162.8 (q, J = 35.6 Hz), 157.6, 157.6, 132.4, 118.5,
42.6, 41.5, 30.6, 30.2, 29.9, 27.7, 23.5, 11.5. HRMS (ESI-MS):
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m/z [M + H+] calculated for C24H45N10S2
+: 537.3265, found
537.3261; C24H44N10S2·4TFA (992.90).
4.2.7.4. 1-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-3-{8-
[3-(3-(2-aminothiazol-5-yl)propyl)guanidino]octyl}guanidine
(63). Prepared from 53 (without puriﬁcation) in DCM (16.0
mL) and TFA (4.0 mL) according to the general procedure, 63
was yielded as a yellow oil (28.3 mg, 7.1%): RP-HPLC: 95%,
(tR = 15.87, k = 3.78).
1H NMR (300 MHz, CD3OD, tetra-
triﬂuoroacetate) δ (ppm) 7.02 (s, 1H), 3.29−3.05 (m, 8H),
2.85−2.55 (m, 4H), 2.19 (s, 3H), 2.00−1.73 (m, 4H), 1.69−
1.50 (m, 4H), 1.46−1.30 (m, 8H). 13C NMR (75 MHz,
CD3OD, tetra-triﬂuoroacetate) δ (ppm) 171.7, 170.3, 157.5,
132.4, 126.7, 123.7, 118.9, 43.1, 42.0, 41.9, 31.0, 30.8, 30.4,
30.2, 27.9, 25.3, 24.0, 12.4. HRMS (ESI-MS): m/z [M + H+]
calculated for C23H43N10S2
+: 523.3108, found 523.3106;
C23H42N10S2·4TFA (978.87).
4.2.8. General Procedure for the Synthesis of the
Benzoylthioureas 70−75. To an ice-cold solution of the
pertinent amine (64−69, 1 equiv) in MeCN, benzoyl
isothiocyanate (1 equiv) was added dropwise. The reaction
was stirred at room temperature (rt) for 2 h, and the organic
solvent was concentrated under vacuum. The residue was
dissolved in DCM (50 mL) and washed three times with H2O
and saturated solution of NaCl. The organic layer was dried
over Na2SO4, and the crude product was puriﬁed by column
chromatography (EtOAc/PE 1/9−1/6 v/v).
4.2.8.1. N-(Isobutylcarbamothioyl)benzamide (70).42 The
title compound was prepared from isobutylamine (64, 1.00 mL,
10.00 mmol) and 10 (1.34 mL, 10.00 mmol) in MeCN (30
mL) according to the general procedure (Rf = 0.41 in EtOAc/
Hex 1:7). The product was obtained as a beige-colored solid
(2.10 g, 89%), mp 79.6 °C. 1H NMR (300 MHz, CDCl3) δ
(ppm) 10.83 (brs, 1H), 8.98 (brs, 1H), 7.88−7.80 (m, 2H),
7.67−7.59 (m, 1H), 7.56−7.48 (m, 2H), 3.55 (td, J = 6.9, 5.4
Hz, 2H), 2.06 (m, 1H), 1.03 (d, J = 6.7 Hz, 6H). 13C NMR (75
MHz, CDCl3) δ (ppm) 179.85, 166.90, 133.59, 131.81, 129.19,
127.41, 53.38, 27.61, 20.29. HRMS (ESI-MS): m/z [M + H+]
calculated for C12H17N2OS
+: 237.1056, found 237.1057;
C12H16N2OS (236.33).
4.2.9. General Procedure for the Synthesis of the
Thioureas 76−81. The corresponding benzoylthiourea (70−
75, 1 equiv) was stirred in a solution of K2CO3 (2.1 equiv) in
MeOH/H2O (7/3 v/v) for 3−5 h at rt. The proportion of
MeOH was evaporated, and the resulting suspension was
extracted with DCM and stirred for 1 h. The organic layer was
dried over Na2SO4, and the crude product was puriﬁed by
column chromatography (DCM/MeOH/7M NH3 in MeOH
95/3/2 v/v).
Because of the thione−thiol tautomerism, a splitting of the
NH−CH2−R-signal could be observed in the following NMR
spectra. Two broad singlets could be noted right next to each
other. In each case, the integration value was exactly 2. For all
of the other symmetric CH2 peaks, this peak splitting was not
shown.
4.2.9.1. N-Isobutylthiourea (76).42 The title compound was
prepared from 70 (2.00 g, 8.46 mmol) and K2CO3 (2.46 g,
17.77 mmol) in MeOH/H2O (7/3 v/v, 50 mL) according to
the general procedure (Rf = 0.38 in DCM/MeOH/NH3
95:5:0.1), yielding a colorless oil (0.78 g, 70%). 1H NMR
(300 MHz, CDCl3) δ (ppm) 6.96 (brs, 1H), 6.32 (brs, 2H),
3.34 + 2.93 (2 brs, 0.9H + 1.1H (thione−thiol tautomerism)),
1.88 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H). 13C NMR (75 MHz,
CDCl3) δ (ppm) 180.76, 51.82, 27.85, 20.23. HRMS (ESI-
MS): m/z [M + H+] calculated for C5H13N2S
+: 133.0794,
found 133.0794; C5H12N2S (132.23).
4.2.10. General Procedure for the Synthesis of the S-
Methylisothioureas (88−99). The appropriate thiourea (76−
87, 1 equiv) was dissolved in 30 mL of MeCN and treated with
methyl iodide (1.1 equiv). The reaction mixture was stirred for
1 h under reﬂuxing, and the solvent was evaporated under
vacuum. The resulting product (HI salt) was washed three
times with 20 mL of diethylether (Et2O) and dried under
vacuum.
4.2.10.1. S-Methyl-N-propylisothiourea (90).43 The com-
pound 84 (1.18 g, 10.00 mmol) was dissolved in MeCN (30
mL) and treated with methyl iodide (0.69 mL, 11.00 mmol)
according to the general procedure (Rf = 0.41 in DCM/
MeOH/NH3 90:10:0.1). The resulting product was obtained as
an orange oil (90·HI, 2.50 g, 96%). 1H NMR (300 MHz,
CDCl3, hydrogen iodide) δ (ppm) 3.30 (t, J = 7.1 Hz, 2H),
2.79 (s, 3H), 1.74 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR
(75 MHz, CDCl3, hydrogen iodide) δ (ppm) 170.49, 46.60,
21.93, 15.28, 11.45. HRMS (ESI-MS): m/z [M + H+]
calculated for C5H12N2S
+: 133.0794, found 133.0796;
C5H12N2S·HI (260.14).
4.2.11. General Procedure for the Synthesis of the N′-Boc-
S-methylisothioureas (100−111). To a solution of the
pertinent isothiourea (88−99) and 1 equiv of triethylamine
(NEt3) in 50 mL of DCM, a solution of Boc2O (1 equiv) in 20
mL of DCM was added dropwise at rt. The reaction mixture
was stirred overnight (rt) and washed with H2O and saturated
solution of NaCl. The organic layer was dried over Na2SO4, and
the crude product was puriﬁed by column chromatography
(EtOAc/PE 1/9−1/5 v/v).
4.2.11.1. N′-tert-Butoxycarbonyl-S-methyl-N-propyliso-
thiourea (102). The reaction was carried out with 90 (2.46
g, 9.46 mmol), NEt3 (1.31 mL, 9.46 mmol), and Boc2O (2.06 g,
9.46 mmol) according to the general procedure (Rf = 0.50 in
EtOAc/Hex 1:8), yielding a colorless oil (1.74 g, 79%). 1H
NMR (300 MHz, CDCl3) δ (ppm) 9.81 (brs, 1H), 3.26 (q, J =
7.3 Hz, 2H), 2.45 (s, 3H), 1.64 (m, 2H), 1.49 (s, 9H), 0.96 (t, J
= 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 173.44,
162.27, 79.17, 45.52, 28.25, 22.65, 13.56, 11.39. HRMS (ESI-
MS): m/z [M + H+] calculated for C10H21N2O2S
+: 233.1318,
found 233.1321; C10H20N2O2S (232.34).
4.2.12. General Procedure for the Guanidinylation
Reaction of 112−126 and 144. To a suspension of the
corresponding amine 6, 7, 8, or 9 (1 equiv), the pertinent N′-
boc-S-methylisothiourea 100−111 or 143 (1 equiv), and HgCl2
(2 equiv) in DCM, NEt3 (3 equiv) was added. The mixture was
stirred overnight at rt. A possible excess of HgCl2 was quenched
with 7 N NH3 in MeOH (3−5 mL). The resulting suspension
was ﬁltered over Celite, and the crude product was puriﬁed by
column chromatography (DCM/MeOH/7 N NH3 in MeOH
98/1/1−95/3/2 v/v/v).
4.2.12.1. 2-tert-Butoxycarbonyl-1-propyl-3-[3-(1-trityl-1H-
imidazol-4-yl)propyl]guanidine (114). The title compound
was synthesized from 6 (808 mg, 2.20 mmol), 102 (510 mg,
2.20 mmol), HgCl2 (1.19 g, 4.40 mmol), and NEt3 (0.91 mL,
6.60 mmol) in DCM (20 mL) according to the general
procedure (Rf = 0.24 in DCM/MeOH/NH3 98:2:0.1). The
product was obtained as a yellow foamlike solid (620 mg, 51%).
1H NMR (300 MHz, CDCl3) δ (ppm) 9.05 (brs, 1H), 7.39−
7.21 (m, 10H), 7.16−7.04 (m, 6H), 6.54 (s, 1H), 3.56−2.95
(m, 4H), 2.57 (t, J = 6.2 Hz, 2H), 1.86 (quint, J = 6.6 Hz, 2H),
1.51 (m, 2H), 1.47 (s, 9H), 0.83 (t, J = 7.4 Hz, 3H). 13C NMR
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(75 MHz, CDCl3) δ (ppm) 164.49, 160.52, 142.38, 140.67,
138.07, 129.73, 128.34, 128.06, 118.25, 75.20, 53.49, 43.03,
40.67, 29.63, 28.69, 28.57, 22.52, 11.53. HRMS (ESI-MS): m/z
[M + H+] calculated for C34H42N5O2
+: 552.3333, found
552.3338; C34H41N5O2 (551.74).
4.2.13. General Procedure for the Synthesis of the
Monomeric Ligands (127−141 and 145). TFA (4.0 mL)
was added to a solution of the protected precursors 112−126
or 144 in DCM (16.0 mL, 20% TFA in DCM), and the mixture
was reﬂuxed overnight until the protecting groups were
removed (TLC control). Subsequently, the solvent was
evaporated in vacuo and the residue was washed three times
with Et2O (each 20 mL). The crude product was puriﬁed by
preparative RP-HPLC (MeCN/0.1% TFA (aq): 5/95−40/60).
All compounds were dried by lyophilization and obtained as di-
triﬂuoroacetates.
4.2.13.1. 1-[3-(1H-Imidazol-4-yl)propyl]-3-propylguani-
dine (129).44 Prepared from 114 (450 mg, 0.82 mmol) in
DCM (16.0 mL) and TFA (4.0 mL) according to the general
procedure, 129 was yielded as a beige-colored solid (310 mg,
87%), mp 126.7 °C. 1H NMR (300 MHz, CD3OD, di-
triﬂuoroacetate) δ (ppm) 8.80 (d, J = 1.3 Hz, 1H), 7.34 (s,
1H), 3.26 (t, J = 7.0 Hz, 2H), 3.15 (t, J = 7.1 Hz, 2H), 2.80 (t, J
= 7.2 Hz, 2H), 1.96 (quint, J = 7.3 Hz, 2H), 1.61 (m, 2H), 0.97
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CD3OD, di-
triﬂuoroacetate) δ (ppm) 157.58, 134.92, 134.57, 116.97, 44.27,
41.58, 28.82, 23.25, 22.56, 11.41. HRMS (ESI-MS): m/z [M +
H+] calculated for C10H20N5
+: 210.1713, found 210.1714;
C10H19N5·2TFA (437.34).
4.2.14. Synthesis of Di-tert-butyl-2-thioxodihydropyrimi-
din-1,3(2H,4H)-dicarboxylat (143).45 To a stirred solution of
142 (871 mg, 7.50 mmol) in THF (150 mL) under argon at 0
°C, hexane (20 mL) and sodium hydride (1.35 g, 33.8 mmol,
60% in mineral oil) were added. After 5 min, the ice bath was
removed, and the reaction mixture was stirred at room
temperature for 10 min. The mixture was cooled to 0 °C
again, di-tert-butyl dicarbonate (3.60 g, 16.5 mmol) was added,
and the ice bath was removed after 30 min of stirring at that
temperature. The resulting slurry was stirred for another 2 h at
room temperature. Then, the reaction was quenched with an
aqueous solution of saturated NaHCO3 (10 mL). The reaction
mixture was poured into water (250 mL) and extracted with
EtOAc (3 × 70 mL). The combined organic layer was dried
over Na2SO4, ﬁltered, and concentrated in vacuo to give 143 as
a yellow solid (1.88 g, 79%), mp 84.7 °C. 1H NMR (300 MHz,
CDCl3) δ (ppm) 3.67 (t, J = 6.9 Hz, 4H), 2.15 (quint, J = 6.9
Hz, 2H), 1.53 (s, 18H). 13C NMR (75 MHz, CDCl3) δ (ppm)
182.68, 153.66, 84.09, 44.26, 27.77, 24.02. HRMS (ESI-MS):
m/z [M + H+] calculated for C14H25N2O4S
+: 317.1530, found
317.1532; C14H24N2O4S (316.42).
4.3. Pharmacological Methods. 4.3.1. Materials. Hista-
mine dihydrochloride was purchased from Alfa Aesar GmbH &
Co. KG (Karlsruhe, Germany). [3H]mepyramine (speciﬁc
activity: 20.0 Ci/mmol), [3H]tiotidine (speciﬁc activity: 78.4
Ci/mmol), [3H]Nα-methylhistamine (speciﬁc activity: 85.3 Ci/
mmol), and [3H]histamine (speciﬁc activity: 25.0 Ci/mmol)
were obtained from Hartmann Analytic (Braunschweig,
Germany). GTPγS was purchased from Roche (Mannheim,
Germany), and [35S]GTPγS was purchased from PerkinElmer
Life Science (Boston) or Hartmann Analytic (Braunschweig,
Germany). [3H]UR-DE257 was synthesized in our laboratories.
All stock solutions were dissolved in millipore water or in a
mixture of Millipore water/DMSO. In all assays, the ﬁnal
DMSO content amounted to <0.5%.
4.3.2. Membrane Preparations.46 Sf9 cells were seeded at
3.0 × 106 cells/mL and infected with a 1:100 dilution of high-
titer baculovirus stocks encoding hH1R + RGS4, h/gp/r H2R +
Gsαs, hH3R Giα2 + Gβ1γ2, or hH4R Giα2 + Gβ1γ2. The cells
were cultured for 48 h before the production of the membrane
preparation according to a previously reported protocol, using 1
mM ethylenediaminetetraacetic acid (EDTA), 0.2 mM phenyl-
methylsulfonyl ﬂuoride, 10 μg/mL benzamidine, and 10 μg/mL
leupeptin as protease inhibitors. Membranes were suspended in
binding buﬀer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM
Tris/HCl, pH 7.4) and stored at −80 °C until use.
4.3.3. Radioligand Binding Assay.14,47−49 Sf9 membranes
were thawed and sedimented by centrifugation at 13 000g at 4
°C for 10 min. The membranes (hH1R + RGS4, hH2R + Gsαs,
hH3R Giα2 + Gβ1γ2, hH4R Giα2 + Gβ1γ2) were resuspended in
a cold (4 °C) binding buﬀer (BB: 12.5 mM MgCl2, 1 mM
EDTA, and 75 mM Tris/HCl, pH 7.4) at a ﬁnal soluble protein
concentration of 2−6 μg per 1 μL BB. Experiments were
performed in 96-well plates (polypropylene (PP) microplates
96 well, Greiner Bio-One, Frickenhausen, Germany) using a
total volume of 100 μL of BB, which contained 40−90 μg of
membrane, 0.05% bovine serum albumin (BSA), the respective
radioligand ([3H]mepyramine 5 nM, [3H]tiotidine 10 nM,
[3H] UR-DE257 20 nM, [3H]Nα-methylhistamine 3 nM, or
[3H]histamine 15 nM), and the investigated ligands at various
concentrations. During the incubation period (60 min) at room
temperature, the plates were shaken at 250 rpm with a
Heidolph Titramax 101 (Heidolph Instruments GmbH & Co.
KG, Schwabach, Germany). Afterward, bound radioligand was
separated from free radioligand by collection of the membranes
on polyethylenimine-pretreated GF/C ﬁlters (Whatman, Maid-
stone, U.K.) using a 96-well Brandel harvester (Brandel Inc.,
Unterföhring, Germany). After two washing steps with binding
buﬀer, ﬁlter pieces were punched and transferred into 1450-401
96-well sample plates (PerkinElmer, Rodgau, Germany).
Scintillation cocktail (200 μL, Rotiszint Eco plus, Roth,
Karlsruhe, Germany) was added, and the plates were sealed
with Plateseal 1450-461 (PerkinElmer, Rodgau, Germany) and
incubated in the dark for 12 h. Radioactivity (dpm) was
measured with a MicroBeta2 1450 scintillation counter
(PerkinElmer). Experimental data were analyzed by nonlinear
regression and were best-ﬁtted to sigmoidal concentration−
response curves using Prism 5.0c software (GraphPad, San
Diego, CA).50
4.3.4. [35S]GTPγS Binding Assay.14,49,51,52 Membranes of Sf9
cells expressing the h/gp/rH2R + Gsαs, hH3R Giα2 + Gβ1γ2, or
hH4R Giα2 + Gβ1γ2 were thawed and sedimented by
centrifugation at 13 000g at 4 °C for 10 min. The membranes
were resuspended in a cold (4 °C) binding buﬀer BB (12.5 mM
MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4) at a ﬁnal
soluble protein concentration of 1 μg per 1 μL BB. All H4R
experiments contained additionally 100 mM NaCl. For
investigations in the antagonist mode, histamine was added
to the reaction mixture (hH2R: 1 μM, hH3,4R: 100 nM).
Experiments were performed in 96-well plates (PP microplates
96 well, Greiner Bio-One, Frickenhausen, Germany) in a total
volume of 100 μL, containing 10 μg of membrane, 1 μM GDP,
0.05% BSA, 20 nCi [35S]GTPγS, and the investigated ligands at
various concentrations. During the incubation period (90 min)
at room temperature, the plates were shaken at 250 rpm with a
Heidolph Titramax 101 (Heidolph Instruments GmbH & Co.
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KG, Schwabach, Germany). Afterward, bound radioligand was
separated from free radioligand by ﬁltration through GF/C
ﬁlters (Whatman, Maidstone, U.K.) using a 96-well Brandel
harvester (Brandel Inc., Unterföhring, Germany). After two
washing steps with binding buﬀer, the ﬁlter pieces were
punched and transferred into 1450-401 96-well sample plates
(PerkinElmer). Unspeciﬁc binding was determined in the
presence of 10 μM GTPγS. Each well was supplemented with
200 μL of scintillation cocktail (Rotiszint Eco plus, Roth,
Karlsruhe, Germany), and the plates were sealed with Plateseal
1450-461 (PerkinElmer, Rodgau, Germany) and incubated in
the dark for 12 h. Radioactivity (ccpm) was measured with a
MicroBeta2 1450 scintillation counter (PerkinElmer). Data
were analyzed by nonlinear regression and were best-ﬁtted to
sigmoidal concentration−response curves with the Prism 5.0c
software (GraphPad, San Diego, CA).
4.3.5. Histamine H1 Receptor Assay on Isolated Guinea Pig
Ileum.15 Guinea pigs of either sex (250−500 g) were stunned
by a blow on the neck and exsanguinated. The ileum was
rapidly removed, rinsed, and cut into segments of 1.5−2.0 cm
length. The tissues were mounted isotonically (preload of 5
mN) in a jacketed 20 mL organ bath that was ﬁlled with
Tyrode’s solution (composition [mM]: NaCl, 137; KCl, 2.7;
CaCl2, 1.8; MgCl2, 1.0; NaH2PO4, 0.4; NaHCO3, 11.9; and
glucose 5.0) supplemented with atropine, at a concentration
not aﬀecting H1 receptors (0.05 μM), to block cholinergic
muscarinic receptors. The bath was aerated with 95% O2/5%
CO2 and heated to 37 °C. During an equilibration period of 80
min, the tissues were stimulated three times with histamine (2
× 1 μM, 1 × 10 μM) followed by washout. Up to four
cumulative CRCs were determined on each tissue: the ﬁrst by
addition of histamine (0.01−30 μM) and the second to fourth
by addition of histamine in the presence of increasing
concentrations of antagonist (preincubation: 10−15 min).
pEC50 diﬀerences were not corrected because four successive
curves for histamine were superimposable under these
conditions (N > 10). Data were analyzed by nonlinear
regression and were best-ﬁtted to sigmoidal concentration−
response curves using Prism 5.0c software (GraphPad, San
Diego, CA).
4.3.6. Histamine H2 Receptor Assay on the Isolated
Guinea Pig Right Atrium (Spontaneously Beating).2,16,53
Hearts were rapidly removed from guinea pigs used for studies
on the ileum (see above). The right atrium was quickly
dissected and set up isometrically in the Krebs−Henseleit
solution under a diastolic resting force of approximately 5 mN
in a jacketed 20 mL organ bath at 32.5 °C. The bath ﬂuid
(composition [mM]: NaCl, 118.1; KCl, 4.7; CaCl2, 1.8;
MgSO4, 1.64; KH2PO4, 1.2; NaHCO3, 25.0; glucose, 5.0;
sodium pyruvate, 2.0), supplemented with (RS)-propranolol
(0.3 μM) to block β-adrenergic receptors, was equilibrated with
95% O2 and 5% CO2. Experiments were started after 30 min of
continuous washing and an additional equilibration period of
15 min. Two successive histamine CRCs displayed a signiﬁcant
desensitization of 0.13 ± 0.02 (N = 16 control organs). This
value was used to correct each individual experiment. For
agonists, two successive concentration−frequency curves were
generated: the ﬁrst for histamine (0.1−30 μM) and the second
for the agonist of interest either in the absence or in the
presence of cimetidine (30 μM, 30 min preincubated).
Additionally, the sensitivity to 30, 100, or 300 μM cimetidine
was checked at the end of each H2R agonist CRC, and a
signiﬁcant reduction of frequency was observed. The relative
potency of the agonist under study was calculated from the
corrected pEC50 diﬀerence (ΔpEC50). pEC50 values are given
relative to the long-term mean value for histamine (pEC50 =
6.16) determined in our laboratory (pEC50 = 6.16 + ΔpEC50).
Data were analyzed by nonlinear regression and were best-ﬁtted
to sigmoidal concentration−response curves using Prism 5.0c
software (GraphPad, San Diego, CA).
4.4. Computational Methods. 4.4.1. Model Preparation.
To examine possible binding modes of the bivalent ligands 5
and 58 at hH2R and of the monovalent ligand 129 at both
hH3R and hH4R, homology models of these receptors were
prepared as follows: For hH4R, the described hH4R model was
used,54 which was based on the inactive state crystal structure
of the hH1R
55 (PDB ID: 3RZE), and the models comprising
hH2R and hH3R were adapted from this model. Model
preparation was essentially performed as described in Wiﬂing
et al.54 using the modeling suite SYBYL-X 2.0 (Tripos Inc., St.
Louis, MO).
4.4.2. Molecular Docking. The most interesting bivalent
compounds 5 and 58 on the one hand and the monomeric
ligand 129 on the other hand were geometry-optimized by
means of Gaussian 0956 at the HF/6-31(d,p) level, attributing
the ligands a formal charge of +2 and +1, respectively. Upon ﬁle
conversion by means of Open Babel57 and assignment of
physiological ionization states by means of ChemAxon (http://
www.chemaxon.com) Marvin 16.3.28.0, 2016 Calculator
Plugins, ﬂexible docking was performed with the software
package Autodock Vina.58 The following hH2R amino acids
were kept as ﬂexible: K18, S75, Q79, Y94, T95, D98, V99,
C102, R161, N168, H169, T170, T171, S172, K173, K175,
V176, V178, N179, E180, G183, D186, G187, T190, W247,
Y250, F251, F254, R257, R260, N266, E267, E270, L274,
W275, G277, Y278. For hH3R, the amino acids T34, M41, Y91,
Y94, V95, W110, L111, D114, Y115, C118, E185, H187, F192,
F193, Y194, W196, L199, A202, S203, E206, W371, Y374,
T375, M378, R381, H387, D391, D394, E395, D398, W399,
L401, W402 were kept as ﬂexible, and for hH4R the residues
R15, M22, Y72, H75, T76, W90, L91, D94, Y95, C98, M150,
K158, E160, S162, E163, F168, F169, S170, W172, L175, T178,
S179, E182, W316, Y319, S320, T323, L326, S330, S331, T333,
S337, Y340, R341, F344, W345, Q347, W348. The search box
was set to a size of 28 Å × 32 Å × 32 Å, centered at the binding
pocket. Up to 20 binding poses were exported for each ligand.
Taking into account the results of the scoring function as well
as experimental data, the respective best poses were selected for
downstream molecular dynamics simulations.
4.4.3. Molecular Dynamics Simulations. To identify the
respective most probable binding pose, 30 ns molecular
dynamics simulations were performed in a water box at 310
K, and subsequently, free energy (MM-GBSA59) calculations
were performed using the Amber 1460 molecular dynamics
package. To determine ligand force-ﬁeld parameters, RESP61
charges were determined by means of Gaussian 0956 at the HF/
6-31(d,p) level, and general amber force ﬁeld62 atom types as
well as RESP61 charges were assigned using antechamber.60
parmchk260 and tleap60 were used for input ﬁle generation. For
ligand guanidine atoms and protein residues, the Amber
ﬀ99SB63 force-ﬁeld parameters were used. The simulation steps
were carried out in an octahedral box comprising an 8.0 Å
TIP3P64 water layer and neutralizing chloride ions.65 The
mbondi2 parameter set was utilized.66,67 The respective systems
were minimized using the steepest descent (2500 steps) and
conjugated gradient (7500 steps) methods without restraints,
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and were subsequently heated from 0 to 100 K over 50 ps in
the NVT ensemble as well as from 100 to 310 K over 450 ps in
the NPT ensemble. During the ﬁrst ns of the 5 ns equilibration
period, initial harmonic restraints of 5 kcal/mol Å2 were applied
to all ligand and receptor atoms, and, beginning from 1 ns,
harmonic restraints on receptor main chain atoms were reduced
from 5.0 to 0.5 kcal/mol Å2 in a stepwise manner and
maintained during the 30 ns simulation. Bonds involving
hydrogen atoms were constrained using SHAKE68 to enable a
frame step size of 2 fs.65,69 Nonbonded interactions were cut oﬀ
at 8.0 Å, and long-range electrostatics were computed using the
particle-mesh Ewald70 method. The Langevin thermostat71,72
with a collision frequency of 1.0 ps−1 and randomly assigned
initial velocities was used to maintain a target temperature of
310 K. The Berendsen barostat73 with isotropic position scaling
and a pressure relaxation time of 1.0 ps was employed to keep
the pressure constant at 1 bar. Data were collected every 10 ps.
H-bond and cluster analysis were performed by means of
CPPTRAJ60 for the entire 30 ns trajectories. Moreover, the
average linkage algorithm74 was applied for cluster analysis,
setting a cluster size of 5, and the programming language
R75−78 was used for the preparation of H-bond plots. Binding
free-energy (MM-GBSA) calculations of the 30 ns trajectories
were performed using MMPBSA.py59 and a frame step size of
10 ps, and the corresponding plots were obtained using the
Prism 5.01 software (GraphPad, San Diego, CA). All other
ﬁgures were created with PyMOL Molecular Graphics system,
version 1.8.2.1 (Schrödinger LLC, Portland, OR).
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